A randomised trial of maintenance weekly paclitaxel versus observation following remission with first-line induction carboplatin and paclitaxel for patients with ovarian cancer
Completed
- Conditions
- Ovarian cancerCancerMalignant neoplasm of ovary
- Registration Number
- ISRCTN48397858
- Lead Sponsor
- The Institute of Cancer Research (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 1200
Inclusion Criteria
1. Histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer
2. Female, aged 18 years and over
3. International Federation of Gynecology and Obstetrics (FIGO) stage III to IV. Receive six cycles of carboplatin/paclitaxel, three-weekly at registration
4. Able to complete quality of life questionnaires
5. Can comply with follow-up requirements. Written informed consent
6. Response to induction treatment (as demonstrated by a Computed Tomography [CT] scan)
Exclusion Criteria
1. Patients with peritoneal carcinomatosis of 'uncertain' origin which is mucin-secreting
2. Histological evidence of an origin in the gastrointestinal tract, bilary system or lung
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method ot provided at time of registration